The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for patients with advanced pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed after chemotherapy. The approval follows a practice-changing phase 3 study showing substantially longer median overall survival versus standard chemotherapy, including stronger benefit in patients with specific tumor-driving gene mutations. Revolution’s pan-RAS strategy is notable because it targets a historically difficult patient segment—advanced PDAC—where durable responses remain rare. The label covers second-line advanced PDAC, and the dosing is positioned as a convenient oral regimen. Analysts and clinicians are framing the clearance as a potential inflection point for RAS inhibition in pancreatic cancer, where prior approaches have often struggled to translate into meaningful survival improvements.